Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $1.02 in the prior trading day, Fate Therapeutics Inc (NASDAQ: FATE) closed at $1.08, up 5.88%. In other words, the price has increased by $5.88 from its previous closing price. On the day, 1.49 million shares were traded. FATE stock price reached its highest trading level at $1.085 during the session, while it also had its lowest trading level at $1.03.
Ratios:
Our goal is to gain a better understanding of FATE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.87 and its Current Ratio is at 7.87. In the meantime, Its Debt-to-Equity ratio is 0.34 whereas as Long-Term Debt/Eq ratio is at 0.32.
On October 27, 2025, Wedbush Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 09 ’26 when TAHL CINDY sold 10,589 shares for $1.06 per share. The transaction valued at 11,275 led to the insider holds 387,081 shares of the business.
Valamehr Bahram sold 5,190 shares of FATE for $5,557 on Jan 09 ’26. The President and CEO now owns 329,708 shares after completing the transaction at $1.07 per share. On Jan 09 ’26, another insider, TAHL CINDY, who serves as the Officer of the company, bought 10,589 shares for $1.06 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 124580472 and an Enterprise Value of -11594528. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.45 while its Price-to-Book (P/B) ratio in mrq is 0.53. Its current Enterprise Value per Revenue stands at -1.625 whereas that against EBITDA is 0.08.
Stock Price History:
The Beta on a monthly basis for FATE is 2.25, which has changed by -0.18400002 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $1.94, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 2.21%, while the 200-Day Moving Average is calculated to be -5.30%.
Shares Statistics:
The stock has traded on average 1.66M shares per day over the past 3-months and 1530860 shares per day over the last 10 days, according to various share statistics. A total of 115.34M shares are outstanding, with a floating share count of 109.75M. Insiders hold about 4.85% of the company’s shares, while institutions hold 71.34% stake in the company. Shares short for FATE as of 1767139200 were 10065114 with a Short Ratio of 6.07, compared to 1764288000 on 8184722. Therefore, it implies a Short% of Shares Outstanding of 10065114 and a Short% of Float of 9.950000000000001.
Earnings Estimates
The stock of Fate Therapeutics Inc (FATE) is currently in the spotlight, with 9.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.26 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$1.1 and -$1.18 for the fiscal current year, implying an average EPS of -$1.15. EPS for the following year is -$1.16, with 9.0 analysts recommending between -$0.91 and -$1.37.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for FATE’s current fiscal year. The highest revenue estimate was $7.8M, while the lowest revenue estimate was $5.28M, resulting in an average revenue estimate of $6.36M. In the same quarter a year ago, actual revenue was $13.63M
